Needham & Company
View Older Stories
-
Candel Therapeutics Announces Proposed $100 Million Public Offering
-
Candel Therapeutics secures $100M royalty funding deal with RTW
-
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
-
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
-
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
-
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
-
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
-
Candel Therapeutics to present phase 3 prostate cancer trial results at SITC
-
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapi
-
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
-
Candel Therapeutics adds systems immunology expert to advisory board
-
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
-
Candel Therapeutics secures $130 million term loan facility with Trinity Capital
-
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
-
Candel Therapeutics reports interim data on CAN-3110 for glioblastoma
-
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
-
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
-
Candel presents prostate cancer trial data showing therapy works across radiation types
-
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
-
Candel Therapeutics to present phase 3 prostate cancer data at ASTRO
-
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
-
Candel Therapeutics adds CAR-T pioneer Carl June to advisory board
-
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
-
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
-
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
-
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
-
Candel receives EMA orphan designation for pancreatic cancer drug
-
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
-
Candel Therapeutics added to five Russell value indexes
-
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
-
Candel Therapeutics (CADL) Announces $15 million Registered Direct Offering of Common Stock
-
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
-
Candel Therapeutics (CADL) Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
-
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
-
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
-
Candel Therapeutics (CADL) offers positive results from Phase 3 CAN-2409 trial
-
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
-
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
-
Candel Therapeutics to Present at Upcoming Investor Conferences
-
Candel Therapeutics (CADL) Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
-
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
-
Candel Therapeutics (CADL) Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409
-
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsi
-
Candel Therapeutics (CADL) and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
-
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
-
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
-
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
-
Candel Therapeutics (CADL) Announces Positive Final Survival Data from Phase 2 Trial of CAN-2409
-
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
